250 related articles for article (PubMed ID: 19029516)
81. A single blind randomized controlled clinical trial of mexiletine in amyotrophic lateral sclerosis: Efficacy and safety of sodium channel blocker phase II trial.
Shibuya K; Misawa S; Kimura H; Noto Y; Sato Y; Sekiguchi Y; Iwai Y; Mitsuma S; Beppu M; Watanabe K; Fujimaki Y; Tsuji Y; Shimizu T; Mizuno T; Nakagawa M; Sawaguchi K; Hanaoka H; Kuwabara S
Amyotroph Lateral Scler Frontotemporal Degener; 2015; 16(5-6):353-8. PubMed ID: 25960085
[TBL] [Abstract][Full Text] [Related]
82. Factors affecting longitudinal functional decline and survival in amyotrophic lateral sclerosis patients.
Watanabe H; Atsuta N; Nakamura R; Hirakawa A; Watanabe H; Ito M; Senda J; Katsuno M; Izumi Y; Morita M; Tomiyama H; Taniguchi A; Aiba I; Abe K; Mizoguchi K; Oda M; Kano O; Okamoto K; Kuwabara S; Hasegawa K; Imai T; Aoki M; Tsuji S; Nakano I; Kaji R; Sobue G
Amyotroph Lateral Scler Frontotemporal Degener; 2015 Jun; 16(3-4):230-6. PubMed ID: 25548957
[TBL] [Abstract][Full Text] [Related]
83. Quantitative strength testing in ALS clinical trials.
Shefner JM; Liu D; Leitner ML; Schoenfeld D; Johns DR; Ferguson T; Cudkowicz M
Neurology; 2016 Aug; 87(6):617-24. PubMed ID: 27385750
[TBL] [Abstract][Full Text] [Related]
84. Controlled trial of nimodipine in amyotrophic lateral sclerosis.
Miller RG; Shepherd R; Dao H; Khramstov A; Mendoza M; Graves J; Smith S
Neuromuscul Disord; 1996 Mar; 6(2):101-4. PubMed ID: 8664560
[TBL] [Abstract][Full Text] [Related]
85. Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive
Benatar M; Wuu J; Andersen PM; Atassi N; David W; Cudkowicz M; Schoenfeld D
Neurology; 2018 Feb; 90(7):e565-e574. PubMed ID: 29367439
[TBL] [Abstract][Full Text] [Related]
86. Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomised, double blind, placebo controlled, phase III study.
Lauria G; Dalla Bella E; Antonini G; Borghero G; Capasso M; Caponnetto C; Chiò A; Corbo M; Eleopra R; Fazio R; Filosto M; Giannini F; Granieri E; La Bella V; Logroscino G; Mandrioli J; Mazzini L; Monsurrò MR; Mora G; Pietrini V; Quatrale R; Rizzi R; Salvi F; Siciliano G; Sorarù G; Volanti P; Tramacere I; Filippini G;
J Neurol Neurosurg Psychiatry; 2015 Aug; 86(8):879-86. PubMed ID: 25595151
[TBL] [Abstract][Full Text] [Related]
87. Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label extension.
Vucic S; Menon P; Huynh W; Mahoney C; Ho KS; Hartford A; Rynders A; Evan J; Evan J; Ligozio S; Glanzman R; Hotchkin MT; Kiernan MC
EClinicalMedicine; 2023 Jun; 60():102036. PubMed ID: 37396808
[TBL] [Abstract][Full Text] [Related]
88. Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis.
Elia AE; Lalli S; Monsurrò MR; Sagnelli A; Taiello AC; Reggiori B; La Bella V; Tedeschi G; Albanese A
Eur J Neurol; 2016 Jan; 23(1):45-52. PubMed ID: 25664595
[TBL] [Abstract][Full Text] [Related]
89. Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials.
Meininger V; Bensimon G; Bradley WR; Brooks B; Douillet P; Eisen AA; Lacomblez L; Leigh PN; Robberecht W
Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Jun; 5(2):107-17. PubMed ID: 15204012
[TBL] [Abstract][Full Text] [Related]
90. Creatine for amyotrophic lateral sclerosis/motor neuron disease.
Pastula DM; Moore DH; Bedlack RS
Cochrane Database Syst Rev; 2012 Dec; 12():CD005225. PubMed ID: 23235621
[TBL] [Abstract][Full Text] [Related]
91. Branched-chain amino acids and amyotrophic lateral sclerosis: a treatment failure? The Italian ALS Study Group.
Neurology; 1993 Dec; 43(12):2466-70. PubMed ID: 8255440
[TBL] [Abstract][Full Text] [Related]
92. A clinical trial of creatine in ALS.
Shefner JM; Cudkowicz ME; Schoenfeld D; Conrad T; Taft J; Chilton M; Urbinelli L; Qureshi M; Zhang H; Pestronk A; Caress J; Donofrio P; Sorenson E; Bradley W; Lomen-Hoerth C; Pioro E; Rezania K; Ross M; Pascuzzi R; Heiman-Patterson T; Tandan R; Mitsumoto H; Rothstein J; Smith-Palmer T; MacDonald D; Burke D;
Neurology; 2004 Nov; 63(9):1656-61. PubMed ID: 15534251
[TBL] [Abstract][Full Text] [Related]
93. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study.
Fang T; Al Khleifat A; Meurgey JH; Jones A; Leigh PN; Bensimon G; Al-Chalabi A
Lancet Neurol; 2018 May; 17(5):416-422. PubMed ID: 29525492
[TBL] [Abstract][Full Text] [Related]
94. Protein misfolding, amyotrophic lateral sclerosis and guanabenz: protocol for a phase II RCT with futility design (ProMISe trial).
Bella ED; Tramacere I; Antonini G; Borghero G; Capasso M; Caponnetto C; Chiò A; Corbo M; Eleopra R; Filosto M; Giannini F; Granieri E; Bella V; Lunetta C; Mandrioli J; Mazzini L; Messina S; Monsurrò MR; Mora G; Riva N; Rizzi R; Siciliano G; Silani V; Simone I; Sorarù G; Volanti P; Lauria G
BMJ Open; 2017 Aug; 7(8):e015434. PubMed ID: 28801400
[TBL] [Abstract][Full Text] [Related]
95. Post-hoc analysis of open-label extension period of study MCI186-19 in amyotrophic lateral sclerosis.
Takei K; Tsuda K; Takahashi F; Palumbo J
Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):64-70. PubMed ID: 28872916
[TBL] [Abstract][Full Text] [Related]
96. Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis.
Louwerse ES; Weverling GJ; Bossuyt PM; Meyjes FE; de Jong JM
Arch Neurol; 1995 Jun; 52(6):559-64. PubMed ID: 7763202
[TBL] [Abstract][Full Text] [Related]
97. Associations between urate levels and amyotrophic lateral sclerosis functional score with edaravone treatment: Post hoc analysis of studies MCI186-16, MCI186-17, and MCI186-19.
Takahashi F; Kano O; Nagano Y; Yoneoka T; Nelson S; Ushirogawa Y
Muscle Nerve; 2022 Nov; 66(5):583-592. PubMed ID: 36054038
[TBL] [Abstract][Full Text] [Related]
98. The ALSFRSr predicts survival time in an ALS clinic population.
Kaufmann P; Levy G; Thompson JL; Delbene ML; Battista V; Gordon PH; Rowland LP; Levin B; Mitsumoto H
Neurology; 2005 Jan; 64(1):38-43. PubMed ID: 15642901
[TBL] [Abstract][Full Text] [Related]
99. Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial.
Statland JM; Moore D; Wang Y; Walsh M; Mozaffar T; Elman L; Nations SP; Mitsumoto H; Fernandes JA; Saperstein D; Hayat G; Herbelin L; Karam C; Katz J; Wilkins HM; Agbas A; Swerdlow RH; Santella RM; Dimachkie MM; Barohn RJ;
Muscle Nerve; 2019 Feb; 59(2):201-207. PubMed ID: 30192007
[TBL] [Abstract][Full Text] [Related]
100. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group.
Borasio GD; Robberecht W; Leigh PN; Emile J; Guiloff RJ; Jerusalem F; Silani V; Vos PE; Wokke JH; Dobbins T
Neurology; 1998 Aug; 51(2):583-6. PubMed ID: 9710040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
